PDS Biotechnology Corporation (NASDAQ:PDSB) Stock Short Interest Report for September

PDS Biotechnology Corporation (NASDAQ:PDSB) was the recipient of a large decrease in short interest in September. As of September 30th, there was short interest totaling 2,770,411 shares, a decrease of 56.8% from the September 15th total of 6,406,521 shares. Currently, 5.4% of the company’s shares are sold short. Based on an average daily trading volume, of 29,130,359 shares, the short-interest ratio is presently 0.1 days.

Analyst Ratings Changes

PDSB has been the topic of a number of research reports. HC Wainwright reiterated a “buy” rating on shares of PDS Biotechnology in a research report on Wednesday, August 26th. Wall Street Zen raised shares of PDS Biotechnology from a “sell” rating to a “hold” rating in a research note on Monday, October 5th. Finally, Weiss Ratings upgraded shares of PDS Biotechnology from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, September 28th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $9.00.

PDS Biotechnology Stock Down 11.9%

Shares of NASDAQ:PDSB traded down $0.19 during trading on Wednesday, reaching $1.41. 9,337,274 shares of the stock were exchanged, compared to its average volume of 8,365,583. The company has a debt-to-equity ratio of 2.73, a current ratio of 0.57 and a quick ratio of 0.57. PDS Biotechnology has a 1-year low of $0.20 and a 1-year high of $1.79. The stock has a fifty day moving average of $0.59 and a two-hundred day moving average of $0.83. The firm has a market cap of $78.92 million, a price-to-earnings ratio of -2.20 and a beta of 1.17.

PDS Biotechnology (NASDAQ:PDSB) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.05). Research analysts anticipate that PDS Biotechnology will post -0.47 earnings per share for the current fiscal year.

Hedge Funds Weigh In On PDS Biotechnology

Several large investors have recently added to or reduced their stakes in the business. Everhart Financial Group Inc. bought a new stake in PDS Biotechnology during the 3rd quarter worth approximately $29,000. Bank of New York Mellon Corp purchased a new stake in shares of PDS Biotechnology in the second quarter worth approximately $60,000. Renaissance Technologies LLC lifted its holdings in shares of PDS Biotechnology by 25.0% in the first quarter. Renaissance Technologies LLC now owns 220,800 shares of the company’s stock valued at $134,000 after purchasing an additional 44,100 shares in the last quarter. Finally, BlackRock Inc. bought a new position in shares of PDS Biotechnology in the second quarter valued at approximately $535,000. Institutional investors own 26.84% of the company’s stock.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation (NASDAQ: PDSB) is a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer and infectious diseases. The company’s technology is designed to stimulate the immune system and generate antigen-specific T-cell responses against diseased cells.

PDS Biotech’s lead investigational product is PDS0101, an immunotherapy designed to target human papillomavirus type 16 (HPV16) antigens E6 and E7. The product is being evaluated in combination with other treatments for HPV16-associated cancers, including cervical, anal, and certain head and neck cancers.